To prescribe or not: a two-center retrospective observational study of antibiotics usage and outcomes of COVID-19 in Turkey.

Autor: Karakoc HN; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA. hkarakocparlayan@ihv.umaryland.edu.; Department of Infectious Diseases and Clinical Microbiology, Bitlis Tatvan State Hospital, Bitlis, Turkey. hkarakocparlayan@ihv.umaryland.edu., Aydin M; Department of Medical Microbiology, Faculty of Medicine, KTO Karatay University, Konya, Turkey., Ozcan SN; Department of Infectious Diseases and Clinical Microbiology, Bitlis Tatvan State Hospital, Bitlis, Turkey., Olcar Y; Department of Infectious Diseases and Clinical Microbiology, Kastamonu State Hospital, Kastamonu, Turkey., Sumlu E; Department of Medical Pharmacology, Faculty of Medicine, KTO Karatay University, Konya, Turkey., Dindar EK; Department of Infectious Diseases and Clinical Microbiology, Bitlis State Hospital, Bitlis, Turkey., Arslan YK; Department of Biostatistics, Faculty of Medicine, Çukurova University, Adana, Turkey., Sajadi MM; Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2024 Sep 09; Vol. 14 (1), pp. 21031. Date of Electronic Publication: 2024 Sep 09.
DOI: 10.1038/s41598-024-72086-8
Abstrakt: This retrospective cohort study conducted in Turkey between December 2020 and June 2022 aimed to assess antibiotic use, bacterial co-infections, and the associated factors on mortality in hospitalized patients with mild-to-severe COVID-19. Among the 445 patients, 80% received antibiotics, with fluoroquinolones being the most common choice, followed by beta-lactams and combinations. Various clinical and laboratory parameters, including symptoms, comorbidities, CCI, oxygen requirements, and CRP levels were observed to be elevated in the antibiotic group. Non-survivors had more ICU admissions and longer hospital stays compared to survivors. We conducted a multivariate Cox regression analysis to evaluate factors related to mortality. However, we did not find an association between antibiotic use and mortality [HR 2.7 (95% CI 0.4-20)]. The study identified significant factors associated with an antibiotic prescription, such as CCI (OR 1.6), CRP (OR 2.3), and ICU admission (OR 8.8), (p < 0.05). The findings suggest re-evaluating the necessity of antibiotics in COVID-19 cases based on clinical assessments, focusing on the presence of bacterial infections rather than empirical treatment. Further research is necessary to more accurately identify patients with bacterial co-infections who would benefit from antibiotic treatment.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje